Oaktree Acquisition Corp. III Life Sciences Unit
Oaktree Acquisition Corp. III Life Sciences does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to target companies in the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors in … Read more
Oaktree Acquisition Corp. III Life Sciences Unit (OACCU) - Net Assets
Latest net assets as of September 2025: $193.00 Million USD
Based on the latest financial reports, Oaktree Acquisition Corp. III Life Sciences Unit (OACCU) has net assets worth $193.00 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($201.25 Million) and total liabilities ($8.25 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $193.00 Million |
| % of Total Assets | 95.9% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Oaktree Acquisition Corp. III Life Sciences Unit - Net Assets Trend (2024–2024)
This chart illustrates how Oaktree Acquisition Corp. III Life Sciences Unit's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Oaktree Acquisition Corp. III Life Sciences Unit (2024–2024)
The table below shows the annual net assets of Oaktree Acquisition Corp. III Life Sciences Unit from 2024 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $187.50 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Oaktree Acquisition Corp. III Life Sciences Unit's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $193.58 Million | 103.24% |
| Total Equity | $187.50 Million | 100.00% |
Oaktree Acquisition Corp. III Life Sciences Unit Competitors by Market Cap
The table below lists competitors of Oaktree Acquisition Corp. III Life Sciences Unit ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PSMC CO. Ltd
KQ:024850
|
$196.26 Million |
|
Daewon Cable
KO:006340
|
$196.28 Million |
|
Shanghai Xin Nanyang Co Ltd
SHG:600661
|
$196.28 Million |
|
Zhejiang Yuejian Intelligent Equipment Co Ltd
SHG:603095
|
$196.31 Million |
|
Kambi Group plc
PINK:KMBIF
|
$196.14 Million |
|
Amazing Microelectronic
TWO:6411
|
$196.12 Million |
|
GLOBALSTAR INC. DL -0001
F:P8S
|
$196.12 Million |
|
Shanghai Research Institute of Building Sciences Group Co. Ltd A
SHG:603153
|
$196.10 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Oaktree Acquisition Corp. III Life Sciences Unit's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares Oaktree Acquisition Corp. III Life Sciences Unit's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.40x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2024-12-31 | $7.63 | $10.68 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Oaktree Acquisition Corp. III Life Sciences Unit utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.04x
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2024 | 0.00% | 0.00% | 0.00x | 1.04x | $-18.75 Million |
Industry Comparison
This section compares Oaktree Acquisition Corp. III Life Sciences Unit's net assets metrics with peer companies in the Shell Companies industry.
Industry Context
- Industry: Shell Companies
- Average net assets among peers: $36,677,338
- Average return on equity (ROE) among peers: -64.57%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Oaktree Acquisition Corp. III Life Sciences Unit (OACCU) | $193.00 Million | 0.00% | 0.04x | $196.19 Million |
| Artius II Acquisition Inc. Class A Ordinary Shares (AACB) | $-60.27K | 0.00% | 0.00x | $198.37 Million |
| Artius II Acquisition Inc. Units (AACBU) | $-60.27K | 0.00% | 0.00x | $205.28 Million |
| Ares Acquisition Corporation II (AACT-UN) | $931.34 Million | 0.00% | 0.08x | $399.77 Million |
| AA Mission Acquisition Corp. (AAM-UN) | $-559.90 Million | 0.00% | 0.00x | $349.76 Million |
| Global Acquisitions Corporation (AASP) | $3.80 Million | -5.26% | 0.34x | $15.42 Million |
| ABV Consulting Inc (ABVN) | $8.75K | -623.31% | 2.50x | $461.96K |
| Atlantic Coastal Acquisition Corp II (ACAB) | $-8.52 Million | 0.00% | 0.00x | $2.44 Million |
| Annabidiol Corp (ACBD) | $-501.57K | 0.00% | 0.00x | $13.62K |
| ACRO Biomedical Co Ltd (ACBM) | $685.87K | -17.12% | 0.46x | $30.04K |
| Huaizhong Health Group Inc (ADAD) | $-19.47K | 0.00% | 0.00x | $3.15K |